BioSpace News Archive

CM Life Sciences, Inc. (the “Company”) announced today that it priced its initial public offering of 38,500,000 units at $10.00 per unit.

IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura ® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology ® , the Journal of the American Academy of Ophthalmolo gy NEW YORK--( BUSINESS WIRE )-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced that President and CEO Athena Countouriotis, M.D., will participate in question and answer sessions at the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the Citi 15th Annual BioPharma Virtual Conference on Sept. 10.

Headlands Research is pleased to announce that on Friday, Aug. 28, its JEM Research Institute clinical trial site in Lake Worth, Florida, successfully dosed the first North American patient in AstraZeneca’s Phase III COVID-19 vaccine trial.

CorePlus Servicios Clínicos y Patológicos, LLC, a high complexity CLIA-certified clinical and anatomic pathology laboratory, today announced the first deployment in the Americas of an artificial intelligence (AI) powered digital pathology solution for detecting prostate cancer at its main facilities in Carolina.

Nurx, the largest digital practice for women’s health, today introduced personalized treatment for headaches and migraines.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September

Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has promoted Jan Adriaan (Arjan) Haverhals to President of Milestone Scientific, replacing Brent Johnston.

Proceeds to support upcoming pivotal PURSUIT Trial in U.S. following recent announcement of positive results from SUI feasibility and preclinical studies

Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery, development and commercialization of therapies for genetic diseases and vaccines, announced that Fujita Health University has received a contract from the Japan Agency for Medical Research and Development (AMED) to initiate Phase I/II cli